Analyzing Complete Genomics (GNOM) and Its Peers
Complete Genomics (NASDAQ: GNOM) is one of 20 publicly-traded companies in the “Medical Software & Technology Services” industry, but how does it weigh in compared to its competitors? We will compare Complete Genomics to similar companies based on the strength of its dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.
Earnings and Valuation
This table compares Complete Genomics and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Complete Genomics Competitors||$413.57 million||-$24.55 million||415.65|
This table compares Complete Genomics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Complete Genomics Competitors||-14.47%||-7.27%||0.23%|
Insider and Institutional Ownership
62.7% of shares of all “Medical Software & Technology Services” companies are held by institutional investors. 26.5% of shares of all “Medical Software & Technology Services” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Complete Genomics and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Complete Genomics Competitors||91||444||842||13||2.56|
As a group, “Medical Software & Technology Services” companies have a potential upside of 15.70%. Given Complete Genomics’ competitors higher probable upside, analysts clearly believe Complete Genomics has less favorable growth aspects than its competitors.
Complete Genomics competitors beat Complete Genomics on 6 of the 8 factors compared.
About Complete Genomics
Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.
Receive News & Ratings for Complete Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Complete Genomics and related companies with MarketBeat.com's FREE daily email newsletter.